Chief Scientific Officer at Solvias reveals how CROs are overcoming manufacturing challenges and harnessing AI to fast-track the development of groundbreaking cell and gene therapies. Daniel Galbraith ...

Tyra Biosciences has announced new data showing that its investigational therapy, TYRA-300, improves bone growth and corrects skeletal abnormalities in preclinical models of achondroplasia and ...

The partnership allows for the further development of AI-designed RNA-targeted therapies for a range of diseases. Creyon Bio, Inc. (Creyon) has announced a landmark global licensing and multi-target ...

A new study reveals how tumours hijack fat metabolism to suppress immune responses – and how a novel antibody, PLT012, may reverse this effect, offering new hope for treating immunotherapy-resistant ...

From first-in-human trial results to emerging AI tools and patient-focused innovations, AACR 2025 offered a clear snapshot of where cancer research is heading. Drug Target Review was on the ground in ...

Claudia Zylberberg, Chair of Kosten Digital, reveals how AI is revolutionising cell and gene therapy, making drug discovery faster and more cost-effective. In the rapidly evolving field of cell and ...

Judy Ashworth, CMO of Novadip Biosciences, shares her journey in advancing treatments for rare paediatric conditions and championing diversity in STEM. Drug Target Review sat down with Judy Ashworth, ...

Researchers at UTHealth Houston have initiated a new stem cell therapy trial aimed at reducing neuroinflammation to prevent Alzheimer’s disease before symptoms emerge, an approach that could ...

Dr Cyril Clarke at ICON Biotech reveals how biomarkers are transforming early-phase clinical trials by offering valuable insights into the safety and efficacy of novel therapies. As our understanding ...

Scientists at the University of Virginia (UVA) School of Medicine have uncovered a crucial mechanism behind the lingering effects of long COVID, revealing how severe COVID-19 infections impair immune ...

Insilico Medicine’s AI-designed drug for idiopathic pulmonary fibrosis (IPF), Rentosertib, has been granted an official name by USAN. This is the first drug where both the target and compound were ...

Insilico Medicine’s AI-designed CDK12/13 inhibitors show promise against treatment-resistant cancers. Find out how this breakthrough could reshape cancer therapy. The study highlights compound 12b, a ...